Hila Magen

4.4k total citations
71 papers, 1.0k citations indexed

About

Hila Magen is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Hila Magen has authored 71 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 37 papers in Molecular Biology and 34 papers in Oncology. Recurrent topics in Hila Magen's work include Multiple Myeloma Research and Treatments (48 papers), Protein Degradation and Inhibitors (20 papers) and Peptidase Inhibition and Analysis (16 papers). Hila Magen is often cited by papers focused on Multiple Myeloma Research and Treatments (48 papers), Protein Degradation and Inhibitors (20 papers) and Peptidase Inhibition and Analysis (16 papers). Hila Magen collaborates with scholars based in Israel, United States and Spain. Hila Magen's co-authors include Eli Muchtar, Morie A. Gertz, Shaji Kumar, Nelson Leung, Francis K. Buadi, Michelle L. Mauermann, David Dingli, Martha Grogan, Paul J. Kurtin and Ellen D. McPhail and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Hila Magen

68 papers receiving 990 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hila Magen Israel	16	539	425	332	135	112	71	1.0k
Stephen Harding United Kingdom	16	642 1.2×	590 1.4×	216 0.7×	287 2.1×	217 1.9×	75	1.2k
Hiroshi Tsutani Japan	16	338 0.6×	439 1.0×	160 0.5×	127 0.9×	123 1.1×	82	979
Elba Reyes‐Maldonado Mexico	17	232 0.4×	346 0.8×	152 0.5×	115 0.9×	40 0.4×	75	976
Bahru Habtemariam United States	12	626 1.2×	176 0.4×	480 1.4×	49 0.4×	36 0.3×	23	1.3k
Masahiro Hirayama Japan	18	216 0.4×	277 0.7×	250 0.8×	92 0.7×	30 0.3×	122	1.2k
Peter A.W. te Boekhorst Netherlands	21	221 0.4×	582 1.4×	263 0.8×	245 1.8×	18 0.2×	50	1.1k
Hongyan Tong China	20	514 1.0×	764 1.8×	225 0.7×	250 1.9×	13 0.1×	169	1.3k
Tor Henrik Anderson Tvedt Norway	18	176 0.3×	632 1.5×	167 0.5×	153 1.1×	36 0.3×	66	1.0k
Margaret Kasner United States	18	368 0.7×	370 0.9×	170 0.5×	86 0.6×	11 0.1×	76	1.1k
Lauren Clancy United States	8	370 0.7×	298 0.7×	238 0.7×	53 0.4×	20 0.2×	13	1.2k

Countries citing papers authored by Hila Magen

Since Specialization

Citations

This map shows the geographic impact of Hila Magen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hila Magen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hila Magen more than expected).

Fields of papers citing papers by Hila Magen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hila Magen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hila Magen. The network helps show where Hila Magen may publish in the future.

Co-authorship network of co-authors of Hila Magen

This figure shows the co-authorship network connecting the top 25 collaborators of Hila Magen. A scholar is included among the top collaborators of Hila Magen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hila Magen. Hila Magen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vainstein, Vladimir, P. Milani, Giovanni Palladini, et al.. (2024). Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature. Acta Haematologica. 148(4). 419–426. 3 indexed citations

Gurion, Ronit, Pia Raanani, Iuliana Vaxman, et al.. (2024). Role of Autologous Transplant in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Triplets: A Systematic Review and Meta-Analysis. Acta Haematologica. 148(4). 468–476. 2 indexed citations

Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S226–S226. 1 indexed citations

Cohen, Yaël C., Daniel Morillo, Moshe E. Gatt, et al.. (2023). MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S478–S479. 1 indexed citations

Kastritis, Efstathios, Giovanni Palladini, Paolo Milani, et al.. (2023). Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study. Cancers. 15(6). 1710–1710. 16 indexed citations

Magen, Hila, Shalev Fried, Orit Itzhaki, et al.. (2023). POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA. Hematological Oncology. 41(S2). 82–83. 1 indexed citations

Magen, Hila, Abraham Avigdor, Shalev Fried, et al.. (2023). Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders. PLoS ONE. 18(5). e0284925–e0284925. 1 indexed citations

Ostrovsky, Olga, Katia Beider, Hila Magen, et al.. (2023). Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma. Cells. 12(6). 913–913. 2 indexed citations

Vainstein, Vladimir, Paolo Milani, Giovanni Palladini, et al.. (2023). Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience. Blood. 142(Supplement 1). 6763–6763. 2 indexed citations

10.

Kaplan, Batia, Olga Kukuy, Michael Arad, et al.. (2023). Diagnostic Challenges and Solutions in Systemic Amyloidosis. International Journal of Molecular Sciences. 24(5). 4655–4655. 4 indexed citations

11.

Magen, Hila, et al.. (2022). Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments. Therapeutic Advances in Hematology. 13. 1543983933–1543983933. 5 indexed citations

12.

Gatt, Moshe E., Iuliana Vaxman, Tamar Tadmor, et al.. (2020). Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review. European Journal Of Haematology. 106(2). 184–195. 18 indexed citations

13.

Magen, Hila, et al.. (2020). Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series. Clinical Lymphoma Myeloma & Leukemia. 20(12). e947–e955. 5 indexed citations

14.

Beider, Katia, Hila Magen, Olga Ostrovsky, et al.. (2020). Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. Journal of Hematology & Oncology. 13(1). 158–158. 38 indexed citations

15.

Avivi, Irit, Moshe E. Gatt, Efrat Luttwak, et al.. (2020). The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data. Leukemia Research. 97. 106429–106429. 1 indexed citations

16.

Usmani, Saad Z., María‐Victoria Mateos, Vânia Hungria, et al.. (2020). Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. Journal of Cancer Research and Clinical Oncology. 147(2). 619–631. 20 indexed citations

17.

Brighton, Timothy, Simon J. Harrison, David Ghez, et al.. (2017). A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma. Blood. 130. 3155–3155. 5 indexed citations

18.

Ganzel, Chezi, Ory Rouvio, Hila Magen, et al.. (2016). Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series. Blood. 128(22). 5699–5699. 1 indexed citations

19.

Muchtar, Eli, Hila Magen, Gilad Itchaki, et al.. (2015). Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. Leukemia Research. 41. 56–61. 4 indexed citations

20.

Muchtar, Eli, Ron Ram, Pia Raanani, et al.. (2014). First line and salvage therapy with total therapy 3-based treatment for multiple myeloma––An extended single center experience. Leukemia Research. 38(12). 1401–1406. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact